Active, not recruitingPHASE2, PHASE3NCT05987956
Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
Studying NON RARE IN EUROPE: Non-small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- Principal Investigator
- Han Xu, MD/PhD/FAPCRMedicine Invention Design, Inc. - IORG0007849 - NPI 1023387701
- Intervention
- Alectinib - Usual(drug)
- Enrollment
- 600 target
- Eligibility
- 22-75 years · All sexes
- Timeline
- 2026 – 2026
Study locations (2)
- Omnicure Clinical Research, Doral, Florida, United States
- Medicine Invention Design, Inc. - IORG0007849 - NPI 1023387701, Rockville, Maryland, United States
Collaborators
UnitedHealthcare · Omnicure Clinical Research
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05987956 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Non-small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07224152NBTXR3 With Radiation Therapy Alone for Locally-advanced Non-small Cell Lung CancerM.D. Anderson Cancer Center
- RECRUITINGPHASE2NCT07104630Pulmonary Rehabilitation in Advanced Lung Cancer SurvivorsCase Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGEARLY PHASE1NCT07274813A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid TumorsShanghai Henlius Biotech
- RECRUITINGPHASE1NCT07358806Study to Assess the Effect of OCT-598 in Patients With Advanced Solid TumorsOscotec Inc.
- RECRUITINGPHASE3NCT06686771Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung CancerCanadian Cancer Trials Group
- RECRUITINGPHASE3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
- RECRUITINGPHASE2NCT06656598Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung CancerIntergroupe Francophone de Cancerologie Thoracique
See all trials for NON RARE IN EUROPE: Non-small cell lung cancer →